Do COMT rs4680 AG and CYP1B1 rs1056836 CG affect estrogen metabolite balance during HRT?

In women undergoing hormone replacement therapy (HRT), such as a 52-year-old female, genetic variations in phase I and phase II enzymes dictate the metabolic fate of exogenous estrogens.

Estrogen hydroxylation and clearance dynamics

• CYP1B1 rs1056836 (Val432Leu): The G (Val) allele in this polymorphism alters phase I estrogen metabolism by increasing the rate of 4-hydroxylation relative to 2-hydroxylation. In vitro models demonstrate up to a threefold increase in catalytic efficiency for the G allele, favoring the production of 4-hydroxyestrogens over the more benign 2-hydroxyestrogens.
• COMT rs4680 AG (Val158Met): This heterozygous genotype results in intermediate catechol-O-methyltransferase activity, causing a 2- to 3-fold decrease in methyltransferase activity compared to the high-activity GG (Val/Val) genotype. This slows down phase II methylation clearance of catechol estrogens into protective methoxyestrogens.

Mechanistic impact of HRT substrate flux

• Magnified metabolic variation: Exogenous HRT increases the absolute availability of estradiol and estrone substrates. This heightened substrate flux magnifies individual enzymatic variations, exposing the limitations of downstream clearance pathways.
• Genotoxic quinone pathway activation: Accumulating catechol estrogens can oxidize into highly reactive, genotoxic estrogen-quinones. Efficient methylation clearance converts these catechol intermediates into stable methoxyestrogens, effectively blocking their oxidation. When CYP1B1 rs1056836 CG increases 4-hydroxyestrogen formation and COMT rs4680 AG limits clearance, the overall metabolite balance shifts toward reactive intermediates and away from protective methoxyestrogens.

Bottom line

The CYP1B1 rs1056836 CG and COMT rs4680 AG genotypes interact during HRT to alter estrogen metabolite balance. By simultaneously accelerating the formation of reactive 4-hydroxyestrogens and slowing their methylation clearance, these variants promote the accumulation of reactive intermediates, highlighting the role of genomic variation in personalized HRT management.